As you will be aware, the Department of Health has asked NICE to conduct an appraisal of pembrolizumab for untreated, recurrent or metastatic squamous cell carcinoma of the head and neck.
Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during early October 2018 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately early December 2018